Repurposing of 5-nitrofuran-3,5-disubstituted isoxazoles: A thriving scaffold to antitrypanosomal agents

Autor(es):Mostrar menos -

Carvalho, Diego B. ; das Neves, Amarith R. ; Portapilla, Gisele B. ; Soares, Ozildeia ; Santos, Larissa B. B. ; Oliveira, Jefferson R. S. ; Vianna, Luan S. ; Judice, Wagner A. S. ; Cardoso, Iara A. ; Luccas, Pedro H. ; Nonato, M. Cristina ; Lopes, Norberto P. ; de Albuquerque, Sergio ; Baroni, Adriano C. M.

• Tipo de documento: Artigo Científico
• Fonte: ARCHIV DER PHARMAZIE; v. N/A, p. 9-pg., 2022-12-19.

Resumo

Chagas disease (CD) is a neglected disease caused by the protozoan Trypanosoma cruzi. The two drugs used in the treatment schedules exhibit adverse effects and severe toxicity. Thus, searching for new antitrypanosomal agents is urgent to provide improved treatments to those affected by this disease. 5-Nitrofuran-isoxazole analogs were synthesized by cycloaddition reactions [3+2] between chloro-oximes and acetylenes in satisfactory yields. We analyzed the structure-activity relationship of the analogs based on Hammett's and Hansch's parameters. The 5-nitrofuran-isoxazole analogs exhibited relevant in vitro antitrypanosomal activity against the amastigote forms of T. cruzi. Analog 7s was the trending hit of the series, showing an IC50 value of 40 nM and a selectivity index of 132.50. A possible explanation for this result may be the presence of an electrophile near the isoxazole core. Moreover, the most active analogs proved to act as an in vitro substrate of type I nitroreductase rather than the cruzain, enzymes commonly investigated in molecular target studies of CD drug discovery. These findings suggest that 5-nitrofuran-isoxazole analogs are promising in the studies of agents for CD treatment. (AU)

• Processo FAPESP: 14/02205-1 - Estudo do comportamento cinético das convertases
• Beneficiário: Wagner Alves de Souza Júdice
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/25112-4 - Avaliação de moduladores da atividade de proteases envolvidas em processos patológicos
• Beneficiário: Wagner Alves de Souza Júdice
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 21/01503-2 - Avaliação dos efeitos de glicosaminoglicanos na atividade de inibidores de cisteíno proteases catepsinas
• Beneficiário: Wagner Alves de Souza Júdice
• Modalidade de apoio: Auxílio à Pesquisa - Regular